Britain's first daily GLP-1 weight-loss pill is generating extraordinary demand before it has even reached pharmacy shelves, with tens of thousands of people already joining waiting lists in a rush to secure private prescriptions. The launch of Wegovy tablets has been described by pharmacists as one of the biggest moments in weight management in recent years, with many expecting demand to remain exceptionally high during the initial rollout.
The surge in interest is being fuelled by several factors: the convenience of taking a daily tablet instead of a weekly injection, impressive clinical trial results and the reality that NHS access could still be years away. Together, they have created a buying frenzy that has left pharmacies preparing for unprecedented demand, while experts warn patients to remain realistic about what the treatment can and cannot achieve.
Waiting Lists Continue To Grow
Demand for the oral version of Wegovy has surged before the medication officially becomes available.
Simple Online Pharmacy said more than 60,000 people had joined its waiting list before launch, with around 10,000 patients already approved and prescribed the medication for dispatch. The company also revealed that pre-orders during the first 24 hours were more than ten times higher than those recorded when Mounjaro, Britain's best-selling weight-loss injection, was introduced.
Major providers, including Boots, Superdrug, Asda, Morrisons Clinic, and Pharmacy2U, have all reported strong interest, with pharmacists increasing stock orders in anticipation of heavy demand. Although suppliers have prepared for the launch, many expect availability to come under pressure if patient interest continues at its current pace.
Why Britons Are Rushing To Buy
Unlike injectable GLP-1 medicines, Wegovy tablets are taken once a day and do not require refrigeration, making them easier to use at home, at work and while travelling.
The tablets contain semaglutide, the same active ingredient found in Wegovy injections and the diabetes medicine Ozempic. For many patients, the appeal lies not in improved effectiveness but in greater convenience.
Research commissioned by Simple Online Pharmacy found that 61 per cent of people who were not currently taking weight-loss medication would rather take a daily tablet than receive weekly injections. More than half said avoiding needles was the biggest advantage, while almost six in ten believed tablets would be easier to travel with and store.
Novo Nordisk has also reported strong uptake in the United States, where more than three million prescriptions have been issued since the medicine launched earlier this year. Significantly, over 80 per cent of patients prescribed the tablets had never previously used GLP-1 injections, suggesting the oral version could attract an entirely new group of users.
How Effective Is Wegovy?
Clinical trials have produced encouraging results, with participants losing an average of 16.6 per cent of their body weight after just over a year of treatment. For many patients, that equated to around three stone and was almost identical to the average weight loss achieved with weekly Wegovy injections.
Researchers have also linked semaglutide with wider health benefits, including improved cardiovascular health and reduced risks associated with obesity, such as type 2 diabetes and heart disease.
However, doctors stress that the medication is intended for adults living with obesity, or those with a body mass index of at least 27 who also have a weight-related health condition. It is not licensed as a cosmetic weight-loss treatment for people simply hoping to slim down before a holiday.
The Downsides Patients Should Know
Despite the enthusiasm surrounding the launch, experts caution that Wegovy is not a miracle cure.
Like other semaglutide treatments, the tablets can cause side effects, particularly when treatment begins. Common reactions include nausea, vomiting, diarrhoea, constipation and stomach discomfort, although symptoms often improve as the body adjusts.
Healthcare professionals also emphasise that the medication should always be combined with a balanced diet, increased physical activity and regular medical supervision rather than being viewed as a standalone solution.
Another growing concern is the rise of counterfeit medicines. Pharmacy leaders have urged patients to buy only from regulated providers after warning that fake weight-loss drugs and cloned pharmacy websites are becoming increasingly common.
Why NHS Approval Matters
Although Wegovy tablets have received regulatory approval for private prescribing, they have not yet been approved for NHS funding by the National Institute for Health and Care Excellence (NICE).
Some experts believe widespread NHS availability may not happen until 2027 or 2028, leaving many eligible patients reliant on private prescriptions in the meantime. Monthly prices currently range from around £79 for starter doses to as much as £229 for higher-strength treatments, raising concerns that access may depend on personal finances rather than clinical need.
Health campaigners have warned this could create a 'two-tier' system, where patients able to pay privately benefit years before wider NHS access becomes available.
Could Demand Continue To Rise?
With waiting lists already stretching into the tens of thousands and pharmacies reporting record levels of interest, demand for Wegovy tablets shows little sign of slowing.
The combination of strong clinical results, the convenience of a once-daily tablet and uncertainty over NHS availability has created exceptional interest among eligible patients. While pharmacies have increased stock ahead of launch, healthcare professionals continue to stress that the medicine should only be prescribed following a clinical assessment and used as part of a broader, medically supervised weight-management programme.
If current demand continues, Wegovy tablets could become one of Britain's most sought-after prescription medicines, highlighting both the growing appetite for effective obesity treatments and the challenges of ensuring fair access while supplies and NHS funding continue to evolve.
